Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TerumoTRUMY +0.50%92 Days Payable is 58.45 as of Jun. 2026, which is 31% below its 10-year median of 84.35. GuruFocus rates TRUMY with a GF Score™ of 92/100 and a GF Value™ of $19.95 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 793 Medical Devices & Instruments companies, Terumo ranks worse than 58.26% on this metric.
Terumo's average Accounts Payable for the
three
months ended in Jun. 2026 was $531 Mil. Terumo's Cost of Goods Sold for the
three
months ended in Jun. 2026 was $829 Mil.
Hence, Terumo's Days Payable for the
three
months ended in Jun. 2026 was 58.45.
The historical rank and industry rank for Terumo's Days Payable or its related term are showing as below:
TRUMY'
s Days Payable Range Over the Past 10 Years
Min: 59.63 Med: 84.35 Max: 109.02
Current: 59.63
During the past 13 years, Terumo's highest Days Payable was 109.02. The lowest was 59.63. And the median was 84.35.
TRUMY's Days Payable is ranked worse than 58.26% of 793
companies
in the Medical Devices & Instruments industry
Industry Median: 68.47
vs TRUMY: 59.63
Terumo's Days Payable
declined
from Jun. 2025 (69.11) to Jun. 2026 (58.45).
It may suggest that Terumoaccelerated paying its suppliers.
The historical data trend for Terumo's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Terumo's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Terumo Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Terumo's Days Payable distribution charts can be found below:
* The bar in red indicates where Terumo's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Terumo's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Terumo (TRUMY) has a Days Payable of 58.45 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Terumo and its competitors. This is 31% below median its historical median of 84.35. Over the past decade, Terumo's Days Payable has ranged from 59.63 to 109.02. According to the industry distribution chart, Terumo ranks #462 out of 793 companies in the Medical Devices & Instruments industry, placing it in the top 58.3%.
Is Terumo's Days Payable too high?
Terumo's current Days Payable of 58.45 is 31% below median its 10-year median of 84.35. Over the past 10 years, this metric has ranged from a low of 59.63 to a high of 109.02. The Medical Devices & Instruments industry median Days Payable is 68.47. Terumo's value of 58.45 is 14.6% below this industry median. Based on the distribution chart, Terumo ranks #462 out of 793 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Terumo has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Terumo's Days Payable compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Terumo ranks #462 out of 793 companies for Days Payable. This places Terumo in the lower half of its industry. The industry median Days Payable is 68.47. Terumo's value of 58.45 is 14.6% below this benchmark. Historically, Terumo's own Days Payable has ranged from 59.63 to 109.02 over the past decade. While the company's 10-year median is 84.35 vs. the industry median of 68.47, Terumo has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.47, based on 793 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Terumo's current Days Payable of 58.45 is 14.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Terumo and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Terumo's current Days Payable is 58.45, which is 31% below median its own 10-year median of 84.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Terumo stock overvalued right now?
Based on GuruFocus' analysis, Terumo (TRUMY) is currently considered Modestly Undervalued. The stock's GF Value™ is $19.95, compared to a current price of $16.23 — trading 18.6% below its estimated fair value. The current Days Payable is 58.45, which is 31% below median its 10-year median of 84.35 and 14.6% below the Medical Devices & Instruments industry median of 68.47. Terumo's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Terumo (TRUMY), the current Days Payable is 58.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Terumo (TRUMY) Overvalued in 2026?
Based on GuruFocus' analysis, Terumo stock appears to be undervalued.
The current stock price of $16.23 is trading 18.6% below its estimated GF Value™ of $19.95.
GuruFocus considers Terumo to be Modestly Undervalued.
Key valuation signals for TRUMY:
Days Payable: 58.45 (31% below median its 10-year median of 84.35)
GF Value™: $19.95 vs. price of $16.23 (18.6% below fair value)
Industry Position: 14.6% below the Medical Devices & Instruments median (#462 of 793)
No single metric tells the full story. See the TRUMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Started as a clinical thermometer producer in Japan in 1921, Terumo is a comprehensive medical device player with a diversified global revenue. Its product portfolio includes prefilled syringes, insulin patch pumps, neurovascular or cardiac vascular interventional devices, and blood processing systems. As of 2025, the cardiac and vascular business is the largest segment, contributing over 60% of its total revenue. Geographically, North America is the largest region, with 38% of Terumo's revenue.
92GF Score
Get the complete analysis for TRUMY
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRUMY has been successfully added to your 
